Moderna/$MRNA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Moderna
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Ticker
$MRNA
Sector
Primary listing
Employees
5,800
Headquarters
Website
Moderna Metrics
BasicAdvanced
$9.7B
-
-$7.53
1.83
-
Price and volume
Market cap
$9.7B
Beta
1.83
52-week high
$69.82
52-week low
$23.15
Average daily volume
11M
Financial strength
Current ratio
3.926
Quick ratio
3.287
Long term debt to equity
7.426
Total debt to equity
7.884
Interest coverage (TTM)
-233.79%
Profitability
EBITDA (TTM)
-3,065
Gross margin (TTM)
-71.44%
Net profit margin (TTM)
-94.31%
Operating margin (TTM)
-106.34%
Effective tax rate (TTM)
1.43%
Revenue per employee (TTM)
$530,000
Management effectiveness
Return on assets (TTM)
-14.78%
Return on equity (TTM)
-27.50%
Valuation
Price to revenue (TTM)
3.135
Price to book
1.03
Price to tangible book (TTM)
1.03
Price to free cash flow (TTM)
-2.757
Free cash flow yield (TTM)
-36.27%
Free cash flow per share (TTM)
-9.067
Growth
Revenue change (TTM)
-39.05%
Earnings per share change (TTM)
-50.99%
3-year revenue growth (CAGR)
-48.85%
3-year earnings per share growth (CAGR)
-38.82%
What the Analysts think about Moderna
Analyst ratings (Buy, Hold, Sell) for Moderna stock.
Bulls say / Bears say
Q2 2025 revenue of $142 million surpassed Wall Street’s $112.9 million estimate, thanks to stronger-than-expected spring COVID booster sales and $800 million in cost cuts, narrowing adjusted loss to $2.13 per share versus the forecast $2.97 (Reuters)
The U.S. Court of Appeals for the Federal Circuit upheld a decision invalidating Alnylam’s patent claims targeting Moderna’s Spikevax in June 2025, strengthening Moderna’s intellectual property and lowering royalty risk (Reuters)
In August 2025, the UK Court of Appeal rejected Pfizer/BioNTech’s attempt to overturn Moderna’s COVID-19 vaccine patent victory, confirming the strength of Moderna’s core mRNA technology patent and reinforcing its global IP position (Reuters)
Moderna cut its 2025 revenue outlook to $1.5–$2.2 billion after deferring UK COVID-19 vaccine deliveries to 2026, causing shares to fall more than 4% despite beating Q2 sales estimates (Reuters)
The company withdrew its FDA application for a combination COVID-19 and flu vaccine in May 2025, pushing a potential launch to 2026 after regulators requested more trial data, highlighting regulatory and development challenges (Reuters)
U.S. HHS canceled over $700 million in funding for Moderna’s late-stage bird flu vaccine development in May 2025, casting doubt on its push to diversify beyond COVID-19 vaccines and raising concerns about pipeline support (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2025.
Moderna Financial Performance
Revenues and expenses
Moderna Earnings Performance
Company profitability
Moderna News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Moderna stock?
Moderna (MRNA) has a market cap of $9.7B as of September 18, 2025.
What is the P/E ratio for Moderna stock?
The price to earnings (P/E) ratio for Moderna (MRNA) stock is 0 as of September 18, 2025.
Does Moderna stock pay dividends?
No, Moderna (MRNA) stock does not pay dividends to its shareholders as of September 18, 2025.
When is the next Moderna dividend payment date?
Moderna (MRNA) stock does not pay dividends to its shareholders.
What is the beta indicator for Moderna?
Moderna (MRNA) has a beta rating of 1.83. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.